• T/CSBME 079-2024 肺癌PET/CT正电子药物临床使用质量验收要求 现行
    译:T/CSBME 079-2024 The quality acceptance requirements for the clinical use of positron emission tomography/computed tomography (PET/CT) for lung cancer are as follows: The image quality of PET/CT for lung cancer should meet the following standards: - Clear image structure, without artifacts or noise - Sufficient contrast between normal and abnormal tissues, and good visualization of pathological changes - Good lesion detection sensitivity and specificity - Good inter-operator reproducibility and inter-scanner reproducibility The quality of the positron emission tomography (PET) imaging agent
    适用范围:范围:本文件适用于临床医疗机构在肺癌PET/CT诊断前,对购买或合规自制的PET/CT正电子药物进行质量验收。本文件不强制所有临床医疗机构在肺癌PET/CT诊断前均执行验收流程,但在诊断过程中怀疑因正电子药物质量问题而影响诊断准确性,建议参考本文件对购买或合规自制的PET/CT正电子药物进行药物质量评估和验收; 主要技术内容:本文件规定了肺癌PET/CT正电子药物临床使用的质量验收要求
    【国际标准分类号(ICS)】 :11.120.10药物 【中国标准分类号(CCS)】 :F54医用同位素
    发布单位或类别:(CN-TUANTI)团体标准 | 发布时间: 2024-02-22 | 实施时间: 2024-05-01